Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 6/20 | 1.00 |
| ▸ | IGF1R | P08069 | 14/20 | 0.69 |
| ▸ | MET | P08581 | 14/20 | 0.69 |
| ▸ | KDR | P35968 | 13/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FES | P07332 | 1/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | FGR | P09769 | 1/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200904 | 0.93 | PTK2B (0.87) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL198261 | 0.91 | PTK2B (1.00) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL19511684 | 0.85 | PTK2B (0.75) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL198023 | 0.83 | PTK2B (1.00) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL19512004 | 0.82 | PTK2B (0.70) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL198072 | 0.81 | IGF1R (1.00) | PTK2BIGF1RMETKDR | |
| SCHEMBL200792 | 0.81 | SYK (0.73) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL198583 | 0.81 | IGF1R (0.75) | PTK2BIGF1RMETKDRAURKA | |
| SCHEMBL19511666 | 0.79 | PTK2B (0.67) | PTK2BIGF1RMETKDRPTK2 | |
| SCHEMBL200905 | 0.79 | PTK2B (1.00) | PTK2BIGF1RMETKDRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | claimed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | claimed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20110229469-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | claimed |
| EP-2349328-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. | 2011-05-05 | — | — | US | claimed |
| WO-2010039248-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2010-04-08 | — | — | WO | claimed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | claimed |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2014-08-28 | — | — | US | disclosed |
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858623-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| WO-2010039248-A1 | METHODS FOR THE TREATMENT OF CANCER | LUDWIG INSTITUTE FOR CANCER RESEARCH (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104161-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | PTK2B 194/4885IGF1R 34/4885MET 1/4885 |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | PTK2B 1450/4885IGF1R 57/4885MET 3/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | PTK2B 1646/4885IGF1R 96/4885MET 3/4885 |
| US-20110229469-A1 | METHODS FOR THE TREATMENT OF CANCER | MET, HGF, EGFR | PTK2B 216/4885IGF1R 34/4885MET 1/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | PTK2B 1450/4885IGF1R 57/4885MET 3/4885 |
| US-20140243339-A1 | COMBINATIONS VEGF(R) INHIBITORS AND HEPATOCYTE GROWTH FACTOR (C-MET) INHIBITORS FOR THE TREATMENT OF CANCER | MET, HGF, HDGF | PTK2B 191/4885IGF1R 34/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.